Mesothelioma News

ATLANTA–(BUSINESS WIRE)–Jun 5, 2006 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today preliminary data from a phase I study of ZIO-201 (isophosphoramide mustard-lysine) were presented at the 2006 American Society of Clinical Oncology Annual Meeting. These data support the Company’s premise that certain adverse events associated with ifosfamide, an approved cancer drug extensively used […]

June 5, 2006
New York, NY, USA | Jun 05, 2006 | The Ludwig Institute for Cancer Research (LICR) and Life Science Pharmaceuticals (LSP) today announced the results of the first clinical trial of monoclonal antibody (mAb) 806, which demonstrate that 806 specifically targets epidermal growth factor receptor (EGFR) on a wide range of tumor types […]

ATLANTA, June 3 /PRNewswire-FirstCall/ — Exelixis, Inc. (NASDAQ: EXEL) announces that updated results from a Phase I trial of XL647 in patients with advanced solid malignancies were reported today. XL647 is an orally bioavailable small molecule inhibitor of HER2, EGFR, VEGFR and EphB4. Study results demonstrate that XL647 is well tolerated and shows evidence of […]